Vera Therapeutics, Inc. Debt Securities, Available-for-sale
Vera Therapeutics, Inc. (VERA) had Debt Securities, Available-for-sale of $450.30 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-10
- 2026-06-30: Debt Securities, Available-for-sale $450.30M.
- 2026-03-31: Debt Securities, Available-for-sale $537.30M.
- 2025-12-31: Debt Securities, Available-for-sale $367.10M.
- 2025-09-30: Debt Securities, Available-for-sale $445.60M.
| Period end | Debt Securities, Available-for-sale | Debt Securities, Available-for-sale as first filed |
|---|---|---|
| 2026-06-30 | $450.30M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $537.30M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $367.10M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $445.60M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $507.70M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $534.70M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $552.80M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $326.10M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $363.30M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $351.50M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $115.00M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $132.50M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $147.10M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $59.80M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $71.20M 10-K · filed 2024-03-27 | $71.19M 10-K · filed 2023-03-28 |
| 2022-09-30 | $83.94M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $81.50M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $39.43M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |